MedPath

Sorbent Therapeutics

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:3
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Phase 2
2 (40.0%)

Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Cross-Linked Polyelectrolyte (CLP)
First Posted Date
2014-03-05
Last Posted Date
2014-03-05
Lead Sponsor
Sorbent Therapeutics
Target Recruit Count
25
Registration Number
NCT02079233

Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers

Phase 1
Completed
Conditions
Basic Science: Safety, Tolerability, Efficacy of CLP
Interventions
Drug: Cross-Linked Polyelectrolyte (CLP)
First Posted Date
2013-09-17
Last Posted Date
2013-09-17
Lead Sponsor
Sorbent Therapeutics
Target Recruit Count
25
Registration Number
NCT01944007
Locations
🇺🇸

Jasper Clinic, Inc., Kalamazoo, Michigan, United States

Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects

Phase 2
Conditions
Heart Failure
Interventions
Drug: placebo
First Posted Date
2012-11-29
Last Posted Date
2014-03-05
Lead Sponsor
Sorbent Therapeutics
Target Recruit Count
270
Registration Number
NCT01736735
Locations
🇺🇸

Orange Country Research Center, Tustin, California, United States

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

Phase 1
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2012-05-15
Last Posted Date
2013-07-19
Lead Sponsor
Sorbent Therapeutics
Target Recruit Count
18
Registration Number
NCT01598740
Locations
🇺🇸

Orange Country Research Center, Tustin, California, United States

Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease

Phase 2
Completed
Conditions
Heart Failure
Interventions
Drug: Placebo
First Posted Date
2010-12-23
Last Posted Date
2013-03-13
Lead Sponsor
Sorbent Therapeutics
Target Recruit Count
113
Registration Number
NCT01265524

News

Courage Therapeutics Appoints Giovanni Ferrara as CEO to Advance Melanocortin-Targeted Obesity Treatments

Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.